Drug Profile


Alternative Names: TOK-001; VN/124; VN/124-1

Latest Information Update: 21 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tokai Pharmaceuticals
  • Developer Novus Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Androgen receptor degradation enhancers; Steroid 17-alpha-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 09 Aug 2017 Discontinued - Phase-I for Prostate cancer (Treatment-resistant) in USA (PO)
  • 09 Aug 2017 Discontinued - Phase-II for Prostate cancer (Hormone refractory, Metastatic disease) in United Kingdom, Spain (PO)
  • 09 Aug 2017 Discontinued - Phase-II for Prostate cancer (Late-stage disease, Treatment-resistant) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top